Non-Invasive Plasma Treatment for Cervical Infections: Targeting High- and Low-Risk HPV Variants
Treatment of Infections of the Cervix Uteri With High- and Low-risk Variants of the Human Papillomavirus Using Non-invasive Physical Plasma
University Hospital Tuebingen
50 participants
Dec 27, 2023
OBSERVATIONAL
Conditions
Summary
This is a prospective, single-center, observational proof-of-principle clinical trial at the Department of Women's Health of the University Hospital Tübingen.
Eligibility
Inclusion Criteria8
- Age ≥ 18 years
- mRNA or DNA-based virus detection by smear (also external findings)
- Clearly visible transformation zone of the cervix and margins of the lesions corresponding to T1/T2
- Written informed consent to participate in the study
- Age ≥ 18 years
- Swab-based mRNA or DNA-based virus detection (also external findings)
- Clearly visible transformation zone of the cervix corresponding to T1/T2
- Written informed consent to participate in the study
Exclusion Criteria3
- Transformation zone not fully visible
- Evidence of invasive disease
- Serious cardiovascular diseases
Interventions
The treatment is administered by either the supervising specialists or assistant doctors at the University Women's Hospital, under their supervision and authorization. It's important to note that the NIPP treatment is designed to be relatively brief, with a duration not exceeding 10-20 minutes.
A potential natural healing of the HPV infection will be anticipated
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06291311